Mucormycosis-“The deadly fungal disease” and its prosthodontic management

Abstract

Coronavirus Disease 2019 (COVID-19), during the second wave in early 2021 has created devastating chaos. Adding more burden to such a challenging situation, mucormycosis an angioinvasive, fulminant fungal infection has seen a sudden surge in patients with COVID -19. Mucormycosis commonly affects immunocompromised patients. Early diagnosis, elimination of the predisposing factor, and surgical debridement, along with antifungal therapy, are the key factors responsible for successful treatment and patient survival. Mucormycosis is presented by various clinical forms. The present paper reviews about the clinical presentation, diagnosis and various treatment modalities for managing mucormycosis-"the deadly fungal disease".